Minerva Neurosciences, Inc

Minerva Neurosciences, Inc

2.20
USD
-0.10
(-4.35%)
-5.56EPS
166.95MMarket Cap
Mar 09Next Earn

Total Valuation

USD

As of September 30, 2026, Minerva Neurosciences, Inc carries a market capitalization of 166.95M, placing it among publicly traded companies globally. Its enterprise value stands at 90.00M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap166.95M
Enterprise Value90.00M

Important Dates

Minerva Neurosciences, Inc's next confirmed earnings release is scheduled for March 9, 2027.

Earnings Date3/9/2027

Share Statistics

As of September 30, 2026, Minerva Neurosciences, Inc has 49.84M shares outstanding.

Shares Outstanding49.84M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio-1.71
P/TBV Ratio-1.49
P/FCF Ratio-5.58
P/OCF Ratio-4.02

Financial Position

As of September 30, 2026, Minerva Neurosciences, Inc maintains a current ratio of 33.02, meaning it holds 33.0x the short-term assets needed to cover near-term liabilities.

Current Ratio33.02
Quick Ratio30.46

Financial Efficiency

These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -460.33, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 7.00, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-460.33
Employee Count7.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Minerva Neurosciences, Inc's stock has declined approximately 46.47% over the past 52 weeks. The 50-day moving average sits at 2.97, while the 200-day moving average is 4.80.

52-Week Price Change-46.47%
50-Day Moving Average2.97
200-Day Moving Average4.80

Income Statement

USD

Over the twelve months ended September 30, 2026, Minerva Neurosciences, Inc generated - - in revenue and converted that into -290.86M in net income, yielding earnings per share of -5.56. EBITDA reached -41.73M, while operating income came in at -41.73M.

Operating Income-41.73M
Pretax Income-290.86M
Net Income-290.86M
EBITDA-41.73M
EBIT-41.73M
Earnings Per Share (EPS)-5.56

Balance Sheet

USD

These figures are as of September 30, 2026. Total book value stands at -97.52M, with working capital of 80.88M providing operational flexibility.

Cash & Cash Equivalents76.94M
Net Debt-20.22M
Equity (Book Value)-97.52M
Book Value Per Share-1.96
Working Capital80.88M

Cash Flow

USD

Minerva Neurosciences, Inc produced -31.40M in operating cash flow over the twelve months ended September 30, 2026.

Operating Cash Flow-31.40M
Free Cash Flow-31.40M
FCF Per Share-0.83

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -17.91: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -57.02, meaning Minerva Neurosciences, Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-57.02
FCF Yield-17.91

Stock Splits

Minerva Neurosciences, Inc's most recent stock split took place on June 21, 2022 with a 8:1 split ratio.

Last Split Date6/21/2022
Split Ratio8:1

Scores

As of September 30, 2026, Minerva Neurosciences, Inc has an Altman Z-Score of -11.66, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-11.66